A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
commercialization with strong product
lifecycle management capability
Focusing on unmet clinical needs, we collaborate with global biotech/biopharma to jointly develop first- or best-in-class innovative products.
Adhering to the patient-centered philosophy, we are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.
Povorcitinib is a selective oral small-molecule JAK1 Inhibitor, with the potential to provide a new treatment option for patients suffering from autoimmune and inflammatory dermatologic diseases On 28 August, Dermavon obtained IND approval for non-segmental vitiligo and moderate to severe hidradenitis suppurativa in China, and is actively preparing for initiating the relevant clinical trials Povorcitinib will synergize with Dermavon’s commercialized innovative drug ILUMETRI, exclusive drug Hirudoid and the innovative drug under development ruxolitinib phosphate cream, etc. China Medical System Holdings Limited (“CMS”or the “Group” ) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details) together with its subsidiaries, received the drug clinical trial approval notice […]
We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.
If you are interested in joining us, or curious about our business and products, please feel free to contact us.